The use of cereton in patients with chronic brain ischemia and moderate cognitive impairment

Close metadata

Recommended articles:

Cerebrolysin in the treatment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3):20-25

Treatment of diseases with consequences of traumatic brain injury. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3):26-33

Improving the effectiveness of pharmacotherapy in comorbid patients with chronic cerebral ischemia on an outpatient basis. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3):51-55

Asthenic post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3):61-69

Study of the effect of Unifuzol on cognitive impairment and damage to the hippocampus and cerebral cortex during course administration to rats with bilateral stenosis of the common carotid arteries, causing chronic circulatory failure. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3):94-103

Chronic cerebral ischemia in therapeutic hospital patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3-2):50-57

Features of treatment and rehabilitation of COVID-19 patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3-2):76-84

Chronic maxillary atelectasis or silent sinus syndrome. Russian Rhinology. 2023;(1):60-65

Diagnosis and treatment of orofacial pain syndromes. Russian Journal of Pain. 2023;(1):5-12

A case of Norwegian scabies in a mental deficiency. Russian Journal of Clinical Dermatology and Venereology. 2023;(2):161-164

Objective. To study the efficacy and safety of cereton in the treatment of patients with chronic brain ischemia and moderate cognitive impairment. Material and methods. The study included 25 patients, 16 women and 9 men, mean age 53,8±1,3 years. Moderate cognitive impairment measured with MMSE and HADS was found in all patients. Quality of life was assessed with SF-36. Somatic and neurological studies as well as brain MRI were carried out. Inpatients received cereton in dose 1000 mg in 200 ml of physiological solution during 15 days, after the discharge from the hospital patients received 1 capsule three times a day during 3 months. Results and сonclusion. Cereton had a significant positive effect on patient's condition including cognitive function. Subjective effect was recorded after 5-6 days of treatment, more evident and stable effect was seen from the 15th day. In the end of treatment, clinicians recorded "moderate" effect in 11 patients and "marked" effect in 8 patients (according to patients' reports, those effects were noted in 9 and 12 cases, respectively). The drug was well-tolerated and had a positive effect on quality of life of the patients.

Keywords:

chronic brain ischemia

moderate cognitive impairment

treatment

cereton

choline alfoscerate

Authors:

N.V. Pizova

Kafedra nevrologii i neĭrokhirurgii Iaroslavskoĭ gosudarstvennoĭ meditsinskoĭ akademii

List of references:

Varakin Yu.Ya. Rasprostranennost' i struktura tserebrovaskulyarnykh zabolevanii v razlichnykh regionakh SSSR po dannym odnomomentnogo epidemiologicheskogo issledovaniya. Zhurn nevrol i psikhiat 2005; 105: 11: 7-10.
Gusev E.I., Konovalov A.N., Skvortsova V.I. i dr. Khronicheskaya nedostatochnost' mozgovogo krovoobrashcheniya. Nevrologiya: natsional'noe rukovodstvo. M: GEOTAR-Media 2010.
Xu W.L., Qiu C.X., Wahlin A. et al. Diabetes mellitus and risk of dementia in the Kungsholmen project. A 6-year follow-up study. Neurology 2004; 63: 1181-1186.
O'Brien J.T., Erkinjuntti T., Reisberg B. et al. Vascular cognitive impairment. Lancet Neurology 2003; 2: 89-98.
Damulin I.V. Legkie kognitivnye narusheniya. Consilium Medicum. 2004; 6: 2: 149-153.
Vereshchagin N.V., Morgunov V.A., Gulevskaya T.S. Patologiya golovnogo mozga pri ateroskleroze i arterial'noi gipertonii. M: Meditsina 1997.
Zakharov V.V., Yakhno N.N. Narusheniya pamyati. M: GEOTAR-Media 2003.
Erkinjuntti T., Roman G., Gauthier S. Treatment of vascular dementia evidence from clinical trials with cholinesterase inhibitors. J Neurol Sci 2004; 226: 63-66.
Jelic V., Winblad B. Treatment of mild cognitive impartment: rationale, present and future strategies. Acta Neurol Scand 2003; 107: 179: 83-93.
Hebert R., Brayne C. Epidemiology of vascular dementia. J Neurol Epidemiol 1995; 14: 240-257.
Petersen R.C., Smith G.E., Waring S.C. et al. Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
Shurdumova M.Kh., Konstantinova E.V. Opyt klinicheskogo primeneniya metabolicheskoi terapii pri ishemii golovnogo mozga. Klinitsist 2013; 3-4: 87-91.
Gusev E.I., Skvortsova V.I. Ishemiya golovnogo mozga. M: Meditsina 2001; 327.
Macario A.J., Conway de Macario E. Sick chaperones, cellular stress, and disease. N Engl J Med 2005; 353: 14: 1489-1501.
Bisschops R.H., Kappelle L.J., Mali W.P., van der Grond J. Hemodynamic and metabolic changes in transient ischemic attack patients: a magnetic resonance angiography and (1)H-magnetic resonance spectroscopy study performed within 3 days of onset of a transient ischemic attack. Stroke 2002; 33: 1: 110-115.
Rutgers D.R., van Osch M.J., Kappelle L.J. et al. Cerebral hemodynamics and metabolism in patients with symptomatic occlusion of the internal carotid artery. Stroke 2003; 34: 3: 648-652.
Muñoz Maniega S., Cvoro V., Armitage P.A. et al. Choline and creatine are not reliable denominators for calculating metabolite ratios in acute ischemic stroke. Stroke 2008; 39: 9: 2467-2469.
Petersen R., Doody R., Kurz A. et al. Current concepts in mild cognitive impairment. Archives of Neurology 2001; 58: 1985-1992.
Avdei G.M. Kompleksnoe lechenie distsirkulyatornoi entsefalopatii. Med novosti 2005; 1: 8-15.
Gusev E.I., Skvortsova V.I. Sovremennye predstavleniya o lechenii ostrogo tserebral'nogo insul'ta. Consilium Medicum 2002; 2: 2: 1-18.
Artem'ev D.V., Zakharov V.V., Levin O.S. i dr. Starenie i neirodegenerativnye rasstroistva: kognitivnye i dvigatel'nye narusheniya v pozhilom vozraste. Pod red. N.N. Yakhno. M: Servier 2005.
Debette S. Vascular risk factors and cognitive disorders. Rev Neurol (Paris) 2013; 169: 10: 757-764.
Kaduszkiewicz H., Zimmermann T., Beck-Bornholdt H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ 2005; 331: 321-327.
Kamchatnov P.R., Abusueva B.A., Evzel'man M.A. i dr. Effektivnost' tseretona pri ostrom ishemicheskom insul'te (rezul'taty issledovaniya SOLNTsE). Zhurn nevrol i psikhiat (Vypusk 2. Insul't) 2012; 3: 10-15.
Tayebati S., Tomassoni D., Di Stefano A. et al. Effect of choline-containing phospholipids on brain cholinergic transporters in the rat. J Neurol Sci 2011; 302: 1-2: 49-57.
Tayebati S., Di Tullio M., Tomassoni D., Amenta F. Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats. J Neurol Sci 2009; 15: 283: 1-2: 187-194.
Parnetti L., Amenta F., Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev 2001; 122: 16: 2041-2055.
De Jesus Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther 2003; 25: 1: 178-193.
Stulin I.D., Musin R.S., Slonimskii D.S. Kholin al'fostserat (tsereton) v lechenii khronicheskoi tserebral'noi ishemii. Zhurn nevrol i psikhiat 2009; 109: 7: 87-89.
Levin O.S., Batukaeva L.A., Anikina M.A., Yunishchenko N.A. Effektivnost' i bezopasnost' kholina al'fostserata (tseretona) u patsientov s bolezn'yu Parkinsona s kognitivnymi narusheniyami. Zhurn nevrol i psikhiat 2009; 109: 11: 42-46.
Batysheva T.N., Kamchatnov P.R., Boiko A.N. i dr. Primenenie tseretona u bol'nykh s umerennymi kognitivnymi rasstroistvami sosudistogo geneza. Trudnyi patsient 2009; 4-5: 42-47.

Close metadata